Agios Pharmaceuticals Inc [AGIO] stock is trading at $35.38, up 3.88%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AGIO shares have gain 6.31% over the last week, with a monthly amount drifted -1.20%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On September 27, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $56 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating. Piper Sandler initiated its recommendation with a Overweight and recommended $41 as its price target on February 03, 2023. Goldman upgraded its rating to Neutral for this stock on November 17, 2022, and upped its price target to $32. In a note dated July 27, 2022, SVB Leerink upgraded an Outperform rating on this stock but restated the target price of $33.
Agios Pharmaceuticals Inc [AGIO] stock has fluctuated between $21.17 and $62.58 over the past year. Currently, Wall Street analysts expect the stock to reach $53.5 within the next 12 months. Agios Pharmaceuticals Inc [NASDAQ: AGIO] shares were valued at $35.38 at the most recent close of the market. An investor can expect a potential return of 51.22% based on the average AGIO price forecast.
Analyzing the AGIO fundamentals
Agios Pharmaceuticals Inc [NASDAQ:AGIO] reported sales of 32.87M for the trailing twelve months, which represents a growth of 21.15%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -12.38%, Pretax Profit Margin comes in at 22.13%, and Net Profit Margin reading is 20.51%. To continue investigating profitability, this company’s Return on Assets is posted at 0.38, Equity is 0.7 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.91 points at the first support level, and at 32.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.15, and for the 2nd resistance point, it is at 36.91.
Ratios To Look Out For
For context, Agios Pharmaceuticals Inc’s Current Ratio is 8.99. As well, the Quick Ratio is 8.77, while the Cash Ratio is 2.12. Considering the valuation of this stock, the price to sales ratio is 61.39, the price to book ratio is 1.24 and price to earnings (TTM) ratio is 3.11.
Transactions by insiders
Recent insider trading involved Milanova Tsveta, Chief Commercial Officer, that happened on Jan 06 ’25 when 2804.0 shares were sold. Officer, Milanova Tsveta completed a deal on Jan 03 ’25 to buy 2804.0 shares. Meanwhile, Director Scadden David sold 200.0 shares on Dec 11 ’24.
